Compare Quest Diagnostics Inc (DGX) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Invesco Preferred ETF — how do they compare? Quest Diagnostics Inc trades at $204.77 (market cap $22.80B), while Invesco Preferred ETF trades at $10.86. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco Preferred ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| DGX | PGX | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | — |
52-Week High | $216.02 | $11.87 |
52-Week Low | $166.42 | $10.82 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
PGX trades at $10.83, down 0.18% with a bearish technical signal from moving averages. Recent news includes the sale of the Golden Sidewalk Project to Kenorland Exploration. Financial ratios are unavailable in the current data, limiting fundamental assessment. The stock faces negative sentiment from recent analyst coverage questioning its risk-reward profile.
The outlook remains cautious given bearish technical indicators and critical analyst commentary highlighting poor returns and limited downside protection. Investment opportunities appear constrained by structural concerns, while risks include participation in market selloffs and recovery rate uncertainties in debt instruments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
